Table 1.

Effect of CEL and its combination with FA on the LDH and CK-MB levels.

Group	Treatment	LDH (IU/L)	CK-MB (IU/L)
I	CONTROL	83.67 ± 4.32	67.17 ± 8.07
II	DOX	213.34 ± 12.06***	181.20 ± 8.02***
III	CEL	105.25 ± 13.34†††	91.02 ± 9.91†††
IV	CEL + DOX	249.60 ± 11.65###	202.67 ± 17.70###
V	FA	87.63 ± 4.68	75.98 ± 4.42
VI	CEL + FA	91.18 ± 2.54*	73.79 ± 6.18*
VII	CEL + FA + DOX	235.33 ± 9.83†	186.60 ± 5.99†

Values are expressed as the mean ± SD and analyzed by one-way ANOVA followed by the Tukey–Kramer multiple comparison test.

^*p < 0.05 (VI vs. III).

^†p < 0.05 (VII vs. IV).

^***p < 0.001 (II vs. I).

^†††p < 0.001(III vs. I)

^###p < 0.001(IV vs. II), DOX: Doxorubicin; CEL: Celecoxib; FA: Folic acid; DOX: Doxorubicin.